Boston Scientific Corporation $BSX Shares Acquired by Capital International Inc. CA

Capital International Inc. CA increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 5.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 191,733 shares of the medical equipment provider’s stock after acquiring an additional 10,718 shares during the quarter. Capital International Inc. CA’s holdings in Boston Scientific were worth $18,719,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Steph & Co. purchased a new stake in shares of Boston Scientific in the 3rd quarter valued at about $25,000. Murphy & Mullick Capital Management Corp boosted its position in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. Financial Consulate Inc. purchased a new position in Boston Scientific during the 3rd quarter worth approximately $25,000. Finally, United Community Bank grew its stake in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Investor alert from TMCNet flags a securities‑fraud lawsuit and solicits investors to consider leading the class action. BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit
• Negative Sentiment: Bragar Eagel & Squire announces an investigation on behalf of long‑term BSX shareholders and invites contact regarding losses. BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire
• Negative Sentiment: Rosen Law Firm public notice: a class action was filed covering the same class period and warns investors to secure counsel before the May 4 deadline. ROSEN Encourages Boston Scientific Investors to Secure Counsel
• Negative Sentiment: Robbins Geller Rudman & Dowd notifies investors of opportunity to seek lead‑plaintiff status in the filed class action (same class period). INVESTOR ALERT: RGRD Law
• Negative Sentiment: Faruqi & Faruqi issues a reminder about the May 4, 2026 deadline for investors to seek lead‑plaintiff appointment in the securities class action. Faruqi & Faruqi Reminder
• Negative Sentiment: Law Offices of Frank R. Cruz encourages BSX shareholders to inquire about a securities fraud class action — another solicitor notice piling on legal attention. Frank R. Cruz Notice
• Negative Sentiment: The Gross Law Firm posts a shareholder notice about a class action and the May 4 deadline to join as a plaintiff. Gross Law Firm Notice
• Negative Sentiment: Portnoy Law Firm announces a class action for investors who bought BSX during the stated class period and highlights the lead‑plaintiff deadline. Portnoy Law Firm Announcement
• Negative Sentiment: Bernstein Liebhard issues a shareholder alert confirming a securities‑fraud class action has been filed against Boston Scientific. Bernstein Liebhard Alert
• Negative Sentiment: Levi & Korsinsky notifies shareholders about the class action and encourages contact before the May 4 deadline. Levi & Korsinsky Notice
• Negative Sentiment: Robbins LLP issues a class action notice covering the same class period and urging investor contact. Robbins LLP Notice
• Negative Sentiment: Unusual options activity: traders bought ~23,040 put contracts on Monday (≈27% above typical put volume), signaling increased bearish positioning or hedging demand. Options Activity Report

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Down 2.8%

Boston Scientific stock opened at $69.90 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific Corporation has a 1-year low of $69.52 and a 1-year high of $109.50. The company has a market cap of $103.72 billion, a PE ratio of 36.03, a price-to-earnings-growth ratio of 1.01 and a beta of 0.69. The stock’s 50 day moving average price is $84.03 and its 200 day moving average price is $93.98.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the prior year, the business posted $0.70 earnings per share. Boston Scientific’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. The Goldman Sachs Group set a $99.00 price target on shares of Boston Scientific in a research report on Thursday, February 5th. TD Cowen dropped their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Stifel Nicolaus decreased their target price on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Finally, Canaccord Genuity Group dropped their price target on Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $108.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.